Merck reaffirms commitment to developing therapeutics to fight infectious diseases

Merck has reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. 

At this year’s 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), researchers are scheduled to present more than 30 scientific data presentations on the Company’s broad portfolio of marketed and investigational anti-infective medicines.

“The rise in infections that are resistant to current antibiotics has become one of the world’s most pressing public health problems,” said Dr. Julie Gerberding, executive vice president, strategic communications, global public policy and population health, Merck. “We at Merck are proud to reaffirm our long-standing commitment to develop new therapeutics to fight infectious diseases, and to continue to collaborate with others to support antimicrobial stewardship to help slow the rate of emerging resistance.”

Merck currently has more than 15 ongoing clinical trials evaluating agents for the prevention and treatment of infectious diseases

Merck completed its acquisition of Cubist Pharmaceuticals on Jan. 21, 2015, and continues to build on both companies’ work in infectious disease. Antimicrobial research remains an important area of focus. In addition to a combined portfolio of antibiotic and antifungal medicines, vaccines, and medicines for HIV and HCV, Merck has multiple programs that span discovery through late-stage development. In total, Merck currently has more than 15 ongoing clinical trials evaluating antibiotic, antifungal and antiviral agents for the prevention and treatment of infectious disease. These trials are projected to enroll approximately 8,000 patients.

Continued innovation in developing new anti-infective medicines is critical to address growing unmet medical needs and mitigate the growing problem of antibiotic and antifungal resistance. In addition to in-house anti-infective research efforts, Merck augments its expertise and resources by collaborating with scientists across the world.

Merck has a long history of collaborating with others in infectious diseases and the company was the first to mass produce penicillin for the war effort in the 1940s. More recently, since 2002, Merck has sponsored the Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART monitors the in vitro susceptibility of clinical bacterial isolates to selected antimicrobials in the United States and internationally. The information collected and shared is designed to help local and global health agencies improve surveillance to better understand trends in antimicrobial resistance and select appropriate antibiotics for patients.